Literature DB >> 11592876

FR901464: total synthesis, proof of structure, and evaluation of synthetic analogues.

C F Thompson1, T F Jamison, E N Jacobsen.   

Abstract

The natural product FR901464 (1) was isolated by the Fujisawa Pharmaceutical Co. and shown to have intriguing biological properties including impressive antitumor activity. In this paper we describe the first total synthesis of 1 in full detail. A chiral building block synthetic strategy was used to assemble the target: optically active components were generated using asymmetric catalytic reactions, and these fragments were coupled together at a late stage in a convergent synthesis. In particular, a versatile, asymmetric hetero-Diels-Alder (HDA) reaction was developed in the context of this synthesis and used with great effectiveness for the preparation of the two densely functionalized pyran rings. The flexible nature of the synthetic route also allowed us to prepare a series of analogues of 1. These compounds were used to prove the relative stereochemistry of the natural product as well as to probe the importance of certain structural features of FR901464 with regard to biological activity.

Mesh:

Substances:

Year:  2001        PMID: 11592876     DOI: 10.1021/ja016615t

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  33 in total

Review 1.  Asymmetric catalysis in complex target synthesis.

Authors:  Mark S Taylor; Eric N Jacobsen
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-12       Impact factor: 11.205

2.  Design and Synthesis of 1,2-Deoxy-pyranose Derivatives of Spliceostatin A toward Prostate Cancer Treatment.

Authors:  Yusuke Yoshikawa; Airi Ishibashi; Tsunayoshi Takehara; Takeyuki Suzuki; Kenichi Murai; Yasufumi Kaneda; Keisuke Nimura; Mitsuhiro Arisawa
Journal:  ACS Med Chem Lett       Date:  2020-05-01       Impact factor: 4.345

3.  A green chemistry approach to asymmetric catalysis: solvent-free and highly concentrated reactions.

Authors:  Patrick J Walsh; Hongmei Li; Cecilia Anaya de Parrodi
Journal:  Chem Rev       Date:  2007-05-27       Impact factor: 60.622

4.  Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue.

Authors:  Brian J Albert; Ananthapadmanabhan Sivaramakrishnan; Tadaatsu Naka; Nancy L Czaicki; Kazunori Koide
Journal:  J Am Chem Soc       Date:  2007-02-06       Impact factor: 15.419

5.  Synthetic mRNA splicing modulator compounds with in vivo antitumor activity.

Authors:  Chandraiah Lagisetti; Alan Pourpak; Tinopiwa Goronga; Qin Jiang; Xiaoli Cui; Judith Hyle; Jill M Lahti; Stephan W Morris; Thomas R Webb
Journal:  J Med Chem       Date:  2009-11-26       Impact factor: 7.446

6.  Garbled messages and corrupted translations.

Authors:  Tilman Schneider-Poetsch; Takeo Usui; Daisuke Kaida; Minoru Yoshida
Journal:  Nat Chem Biol       Date:  2010-03       Impact factor: 15.040

7.  Structural requirements for the antiproliferative activity of pre-mRNA splicing inhibitor FR901464.

Authors:  Sami Osman; Brian J Albert; Yanping Wang; Miaosheng Li; Nancy L Czaicki; Kazunori Koide
Journal:  Chemistry       Date:  2010-11-19       Impact factor: 5.236

8.  Enantioselective Synthesis of Spliceostatin G and Evaluation of Bioactivity of Spliceostatin G and Its Methyl Ester.

Authors:  Arun K Ghosh; Guddeti Chandrashekar Reddy; Andrew J MacRae; Melissa S Jurica
Journal:  Org Lett       Date:  2017-12-08       Impact factor: 6.005

9.  Optimization of antitumor modulators of pre-mRNA splicing.

Authors:  Chandraiah Lagisetti; Gustavo Palacios; Tinopiwa Goronga; Burgess Freeman; William Caufield; Thomas R Webb
Journal:  J Med Chem       Date:  2013-12-11       Impact factor: 7.446

10.  Spliceostatin hemiketal biosynthesis in Burkholderia spp. is catalyzed by an iron/α-ketoglutarate-dependent dioxygenase.

Authors:  Alessandra S Eustáquio; Jeffrey E Janso; Anokha S Ratnayake; Christopher J O'Donnell; Frank E Koehn
Journal:  Proc Natl Acad Sci U S A       Date:  2014-08-05       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.